deltatrials
Terminated PHASE4 INTERVENTIONAL 1-arm NCT05125679

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis (G-CARE)

A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

Sponsor: Janssen-Cilag Ltd.

Conditions Psoriasis
Interventions Guselkumab
Updated 21 times since 2021 Last updated: Mar 28, 2025 Started: Nov 23, 2021 Primary completion: Jul 28, 2023 Completion: Jul 28, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated (A strategic decision was made not to further execute the study. This decision was not based on a safety concern)

Other terminated trials from Janssen-Cilag Ltd.

More terminations from Janssen-Cilag Ltd.

Other Psoriasis trials with similar outcome

Browse all Psoriasis trials

Listed as NCT05125679, this PHASE4 trial focuses on Psoriasis and remains terminated or withdrawn. Sponsored by Janssen-Cilag Ltd., it has been updated 21 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Apr 2025 · 59 days · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Apr 2025 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Feb 2025 — Apr 2025 [monthly]

    Terminated PHASE4

  4. Sep 2024 — Feb 2025 [monthly]

    Terminated PHASE4

  5. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

▶ Show 16 earlier versions

  1. Sep 2023 — Jul 2024 [monthly]

    Terminated PHASE4

    Status: Active Not Recruiting → Terminated

  2. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  3. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE4

  4. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE4

  5. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE4

  6. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE4

  7. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE4

  8. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE4

  9. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

  10. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE4

  11. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE4

  12. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE4

  13. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE4

  14. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE4

  15. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  16. Dec 2021 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen-Cilag Ltd.
Data source: Janssen-Cilag Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations